Jablonec Nad Nisou 1

Researchers are evaluating the effects of the drug orforglipron compared with a placebo on cardiovascular outcomes in adults who have atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). This is a Phase 3, randomized, double-blind, placebo-controlled study designed to investigate major adverse cardiovascular events over a long period. Participants will receive either orforglipron or a placebo orally. The study is event-driven and will continue until the occurrence of major cardiovascular events or up to about 5 years. The treatments are administered without revealing to participants which group they are in to ensure unbiased results. During the study, participants will be monitored for the time to the first occurrence of a major cardiovascular event. Researchers will collect data from baseline through the end of the study, which lasts approximately 5 years. Regular assessments will help evaluate the safety and effects of the treatments on cardiovascular health in this population.

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.

Pancreatic cancer is a disease with a poor prognosis due to its late detection and rapid progression. This research evaluates the performance of the medical software "Lipidica" designed to analyze lipid profiles from blood samples to screen for pancreatic cancer in people at high risk due to family history, genetic mutations, or hereditary pancreatic diseases. The goal is to confirm that this software can distinguish between patients with pancreatic cancer and those at increased risk without cancer. Participants will provide blood samples and undergo medical imaging, including endoscopic ultrasonography, magnetic resonance, and computed tomography, with each imaging method performed up to three times during the study. The software processes lipidomic data alongside laboratory tests measuring markers like CA 19-9, CEA, HbA1c, and hCG (for women of childbearing potential). The study includes a baseline visit and an end-of-study visit, with some participants having an additional visit depending on initial results. Throughout the average three-year participation, researchers will monitor participants using blood tests and imaging to assess the software's ability to differentiate pancreatic cancer cases from high-risk individuals. The main outcome is an interim analysis one year after the first participant enrolment and continuing through study completion. This includes safety monitoring and medical evaluations with the aim of improving early detection methods for pancreatic cancer in high-risk groups.

Overactive bladder (OAB) is a common health issue affecting many adults, with about 15-20% of the population experiencing it. This research aims to increase awareness and ensure that people with OAB symptoms are correctly referred to specialists such as gynecologists, urogynaecologists, or urologists for proper diagnosis and treatment. The study uses an online screening tool to identify individuals who might have OAB and need specialist evaluation. Participants will use a web platform or mobile app to complete validated questionnaires about their urinary symptoms, personal and family medical history, and quality of life. Those with positive screening results will be referred to a specialist who can access their screening data through the platform, perform further diagnostic tests if needed, confirm or rule out OAB, and decide on appropriate treatment. The study also includes a public relations campaign to encourage participation and improve awareness. During the study, participants will complete the online screening and may attend face-to-face specialist visits for diagnosis. Researchers will monitor the number of participants who complete the screening, the percentage of those with suspected OAB agreeing to follow-up, those diagnosed by specialists, and those who attend follow-up visits up to nine months. The data collected will help evaluate the screening process and its impact on quality of life, with attention to safety and privacy under GDPR.